Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Consensus Rating of “Buy” from Brokerages

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) have received a consensus recommendation of “Buy” from the seven brokerages that are presently covering the company, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $29.00.

ATXS has been the topic of several research analyst reports. Citigroup reissued an “outperform” rating on shares of Astria Therapeutics in a report on Wednesday, August 13th. Cantor Fitzgerald reissued an “overweight” rating and issued a $47.00 target price on shares of Astria Therapeutics in a report on Wednesday, May 14th. HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of Astria Therapeutics in a report on Wednesday, August 13th. Finally, JMP Securities boosted their target price on shares of Astria Therapeutics from $25.00 to $26.00 and gave the stock a “market outperform” rating in a report on Wednesday, August 13th.

Institutional Investors Weigh In On Astria Therapeutics

Several large investors have recently bought and sold shares of ATXS. JPMorgan Chase & Co. increased its position in Astria Therapeutics by 39.6% in the fourth quarter. JPMorgan Chase & Co. now owns 54,664 shares of the biotechnology company’s stock worth $489,000 after purchasing an additional 15,520 shares during the last quarter. Wells Fargo & Company MN increased its position in Astria Therapeutics by 47.3% in the fourth quarter. Wells Fargo & Company MN now owns 23,569 shares of the biotechnology company’s stock worth $211,000 after purchasing an additional 7,563 shares during the last quarter. Legal & General Group Plc increased its position in Astria Therapeutics by 7.6% in the fourth quarter. Legal & General Group Plc now owns 31,418 shares of the biotechnology company’s stock worth $281,000 after purchasing an additional 2,222 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Astria Therapeutics in the fourth quarter worth $707,000. Finally, Barclays PLC increased its position in Astria Therapeutics by 5.6% in the fourth quarter. Barclays PLC now owns 97,820 shares of the biotechnology company’s stock worth $875,000 after purchasing an additional 5,169 shares during the last quarter. Institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Stock Performance

ATXS stock opened at $6.42 on Tuesday. Astria Therapeutics has a one year low of $3.56 and a one year high of $12.92. The company’s fifty day moving average price is $6.32 and its 200-day moving average price is $5.70. The company has a market capitalization of $362.34 million, a PE ratio of -3.19 and a beta of 0.48.

Astria Therapeutics (NASDAQ:ATXS) last released its earnings results on Tuesday, August 12th. The biotechnology company reported ($0.57) EPS for the quarter, topping the consensus estimate of ($0.61) by $0.04. On average, research analysts predict that Astria Therapeutics will post -1.65 EPS for the current fiscal year.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.